Upstate Active Clinical Trials
Study Title:
NRG-LU007: RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC: RAPTOR trialWhat is the purpose of the study? (in Layman's terms, please describe the study)
Can we extend the time without your extensive small cell lung cancer growing or spreading by adding radiation therapy to the usual treatment for this type of cancer (an immunotherapy drug called atezolizumab)?Upstate Institutional Review Board (IRB) Number:
1667413Study/Protocol ID:
NRG-LU007Study Phase:
II/IIIPatient Age Group:
AdultsPrincipal Investigator:
Michael D Mix, MDWhat is involved if I participate?
- How long is the study?
After you finish chemotherapy and Atezolizumab, you will either get Atezolizumab alone until your disease gets worse or the side effects become too severe, or you will get Atezolizumab with radiation therapy during the first 5 weeks of treatment, then Atezolizumab alone until your disease gets worse or the side effects become too severe. - Is transportation provided or reimbursed?
No - Is parking provided or reimbursed?
Yes - What tests and procedures are involved?
Please contact the CRA for more information.
Where will the study take place?
SUNY Upstate Cancer Center -all proceduresVerona Cancer Center - all procedures
Oswego - all procedures
Hill Medical Center - RT
Other Information:
Please contact the CRA for more informationClinicalTrials.Gov ID:
NCT04402788For more information about this trial go to ClinicalTrials.Gov
Who can I contact for more information?
Name: Erin Bingham, CCRP
Phone: 315-464-3603
Email: [email protected]